2Department of General Surgery, Ege University Faculty of Medicine, İzmir-Turkey
3Department of Pathology, Ege University Faculty of Medicine, İzmir-Turkey
4Department of Pathology, Manisa State Hospital, Manisa-Turkey
5Department of Radiation Oncology, Dokuzeylül University Faculty of Medicine, İzmir-Turkey
6Department of Biostatistics, Ege University Faculty of Medicine, İzmir-Turkey DOI : 10.5505/tjo.2017.1386 OBJECTIVE
The aim of the present study was to evaluate rate of cyclin D1 expression and examine its relationship to clinicopathological factors and impact on prognosis in breast cancer patients.
METHODS
Total of 85 estrogen receptor (ER)-positive breast cancer patients were included. Expression of cyclin D1, ER, progesterone receptor (PR), and Ki-67 were determined using immunohistochemistry evaluation.
RESULTS
Patients" median age was 49 years (range: 27-83 years) and cyclin D1 was positive in 90.5% of the patients. Cyclin D1 expression was positively correlated with rate of ER positivity and Ki-67 expression (r=0.4; p<0.0001 and r=0.3; p=0.001, respectively). Five-year disease-free and overall survival (OS) rates were not different between patients with or without cyclin D1 expression (81% vs 79% and 93% vs 87%; p=0.8 and 0.4, respectively). High modified Bloom-Richardson grade (p=0.04), high nuclear grade (p=0.021), and PR negativity (p=0.011) were found to be poor prognostic factors for OS rate in univariate analysis.
CONCLUSION
In this study, cyclin D1 was not found to be prognostic factor; however, it is correlated with ER positivity and Ki-67 expression in breast cancer patients.